Christopher J. Reinhard
Executive Chairman of the Board of Directors
Christopher J. Reinhard has been our Executive Chairman of the Board of Directors since June 2004. Since December 2003, Mr. Reinhard has also served as Chairman of the Board and Chief Executive Officer of Cardium Therapeutics, Inc., a public biotechnology company. From July 2002 to December 2004, Mr. Reinhard served as Chief Executive Officer of Collateral Therapeutics, Inc., a public biotechnology company. Prior to the acquisition of Collateral Therapeutics, Inc. by Schering AG in July 2002, Mr. Reinhard worked for Collateral Therapeutics in a variety of roles from June 1995 to July 2002, including Chief Financial Officer and President. Mr. Reinhard holds a B.S. in Finance and an M.B.A. from Babson College.
Douglas Abel
Director
Douglas Abel has been a director since May 2008. Mr. Abel is Chief Executive Officer and a director of Manhattan Pharmaceuticals, Inc., a publicly traded pharmaceutical company. Prior to joining Manhattan Pharmaceuticals, Mr. Abel served as the President and Chief Executive Officer of Tarpan Therapeutics, Inc., a privately-held biopharmaceutical company, from November 2004 until April 2005, when Tarpan Therapeutics was acquired by Manhattan Pharmaceuticals. From 2000-2004, Mr. Abel served at Biogen Idec Inc., where his last position was Vice President of the Dermatology Business Unit. Before that, Mr. Abel served at Allergan, Inc. from December 1987 to August of 2000, where his last position was Director of Marketing, Botox®. Mr. Abel has more than 20 years of product development and marketing experience in the aesthetic cosmetics and medical dermatology industry. He holds an B.A. in Chemistry from Lafayette College and an M.B.A. from Temple University.
John R. Costantino
Director
John R. Costantino has been a director since June 2006. Since January 2006, Mr. Costantino has also served as Managing General Partner of NGN Capital LLC, a venture capital advisory firm focusing on the healthcare and biotechnology industries. He has served as Vice President of Walden Capital Partners L.P., a Small Business Investment Company (SBIC), since 1994, and has been a Managing Director at Walden Partners Ltd., a merchant bank providing consulting and investing services, since 1992. Mr. Costantino currently also serves on the board of directors of GE Funds, GE Investment Funds, Inc., GE Institutional Funds and GE LifeStyle Funds, each management investment companies. Mr. Costantino holds a B.S. from Fordham University and a J.D. from Fordham Law School. He is also a Certified Public Accountant.
Todd C. Davis
Director
Todd C. Davis has been a director since February 2008. Mr. Davis is Co-Founder and Managing Director of Cowen Healthcare Royalty Partners. Mr. Davis was previously a Partner at Paul Capital Partners, where he was focused on the activities of the Paul Royalty Funds. Prior to that, Mr. Davis was a Partner at Apax Partners, a private equity fund. Mr. Davis has extensive healthcare operating experience, having worked in business development and general management at Elan Pharmaceuticals, and in sales and marketing at Abbott Laboratories. He is a former U.S. naval officer and holds a B.S. from the U.S. Naval Academy, and an MBA from Harvard Business School.
Beverly A. Huss
Director
Beverly A. Huss has been a director since October 2007. Ms. Huss is Chief Executive Officer of Vibrynt, Inc., a venture-backed medical device company. From 2001-2005 Ms. Huss served as President, Endovascular Solutions and Vice President of Guidant Corporation where she was responsible for research and development, manufacturing, sales, marketing, finance, regulatory affairs, quality assurance, clinical affairs and human resources within Endovascular Solutions. Additionally, she serves on the board of directors of Dade Behring, Inc. (Nasdaq: DADE), a public company in the medical device and diagnostic testing industry. Ms. Huss holds a B.S. in Metallurgical Engineering from University of Illinois and a Masters in Technology Management from Pepperdine University.
Lon E. Otremba
Director
Lon E. Otremba has been a director since March 2006. He is the Principal Managing Partner of Lon E. Otremba, Strategic and Operational Management Advisory, a management advisory firm. Mr. Otremba most recently served as Chief Executive Officer and a director of Muzak, LLC, a leading provider of commercial music services, from September 2003 to July 2005. Prior to joining Muzak, Mr. Otremba served as Executive Vice President, Strategic Planning and Operations of the AOL Interactive Marketing Group of Time Warner, from May 2002 to August 2003, and as Executive Vice President, Strategic Planning, of the AOL Time Warner Local Partnership Group from February 2001 to April 2002. From November 2000 to January 2002, Mr. Otremba served as Chief Executive Officer and a director of a privately held technology company. Mr. Otremba currently also serves on the board of directors of Cardium Therapeutics, a public interventional cardiology company, and on the board of a non-profit, independent school in Roslyn, New York. Mr. Otremba holds a B.A. in marketing and economics from Michigan State University.
Robert B. Sherman
Director
Robert B. Sherman has been a director since October 2007. Mr. Sherman is a member of the Pilot Group, LLC, a private equity firm. From 2002- 2005 he was America Online, Inc.’s (AOL) President, Interactive Marketing. Prior to AOL, from 2001- 2002, Mr. Sherman was president of Time Warner Cable Advertising Sales. He also formerly served as Executive Vice President of NBC‘s owned and operated radio stations and Chief Executive Officer of the advertising agency Della Femina, Travisano, Sherman & Olken, whose clients have included USA Network and Fox Television. Mr. Sherman holds a B.A. in Psychology from Adelphi University.
